Overall, our results have confirmed that GPS2 functions as a tumor suppressor, as previously suggested by multiple evidences from genomic profiling of human cancer biopsies and by in vitro data from liposarcoma (Pugh et al., 2012; Huang et al., 2016; Priestley et al., 2019). Here, GPS2 is linked to liposarcoma.